SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-010013
Filing Date
2024-03-15
Accepted
2024-03-15 08:00:25
Documents
15
Period of Report
2024-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40077
2 ex99-1.htm EX-99.1 181382
  Complete submission text file 0001493152-24-010013.txt   419512

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20240315.xsd EX-101.SCH 3027
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20240315_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20240315_pre.xml EX-101.PRE 22367
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3658
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 24752512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)